## **INITIAL REMS APPROVAL: JULY 11, 2011**

## NDA 20-931 TIKOSYN (DOFETILIDE)

Antiarrhythmic

Pfizer, Inc.

235 East 42<sup>nd</sup> Street

New York, NY 10017

# **RISK EVALUATION AND MITIGATION STRATEGY (REMS) DOCUMENT**

# I. GOALS

To mitigate the risk of Tikosyn induced arrhythmia by:

- Ensuring that Tikosyn is prescribed only by certified prescribers, dispensed only by certified dispensers, and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;
- Informing patients about the serious risks associated with Tikosyn therapy.

# **II. REMS ELEMENTS**

## A. Medication Guide

A Medication Guide will be dispensed with each Tikosyn prescription in accordance with 21 CFR 208.24 and by Healthcare Providers (HCPs) as described below.

## **B.** Elements to Assure Safe Use

## 1. Healthcare providers who prescribe Tikosyn will be specially certified

- Pfizer will ensure that healthcare providers who prescribe Tikosyn (Prescribers) are specially certified. To become certified, each prescriber will enroll in the Tikosyn Program by submitting to Pfizer a completed Prescriber Certification Form, and agreeing to the following:
  - i. I understand that patients initiated or re-initiated on Tikosyn should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of

creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;

- ii. I understand that following the treatment initiation and dosing guidelines in the Tikosyn label will decrease the risk of Tikosyn induced arrhythmia;
- iii. I will inform my patients that Tikosyn is associated with the risk of induced arrhythmias;
- iv. I will inform my patients that their blood lab measures and ECG should be reevaluated every 3 months;
- v. I will provide the Tikosyn Medication Guide to each patient at the initiation and reinitiation of Tikosyn therapy. I will review the contents of the Medication Guide with each patient.
- b. Pfizer will require a one-time re-certification of all currently certified prescribers within 6 months after REMS approval.
- c. Within 30 days of the initial approval of the Tikosyn REMS, Pfizer will send Dear Healthcare Provider Letters to all currently certified prescribers to notify them of the need to re-certify. The re-certification letter will reinforce the safety messages, safe use conditions, and REMS program elements. The letter will include a copy of the Tikosyn Full Prescribing Information, Medication Guide, Tikosyn Treatment Guidelines and Certification form, and will be available on the Tikosyn REMS program website for 6 months from the date of issuance of the letter.
- d. Pfizer will assess the need for additional, future re-certification of prescribers based on the results of assessments and monitoring.
- e. The Prescriber Certification Forms will be archived in the Pfizer National Tikosyn Database and a confirmation letter will be sent by Pfizer to the certified prescribers.
- f. The following prescriber materials are part of the REMS and are appended:
  - 1. Dear Healthcare Provider Letter for re-certification
  - 2. Dear Healthcare Provider Letter for new enrollees
  - 3. Tikosyn Program Treatment Guidelines
  - 4. Prescriber Certification Form
  - 5. Tikosyn REMS Website

# **2.** Tikosyn will only be dispensed by pharmacies and health care settings that are specially certified

a. Pfizer will ensure that Tikosyn will be dispensed only by pharmacies and health care settings that are specially certified. To be certified to dispense Tikosyn, each pharmacy and healthcare setting will be enrolled in the Tikosyn program.

The enrollment process is comprised of the following steps that must be completed:

- i. Each health care setting where Tikosyn is dispensed for use will designate a representative. The designated representative will enroll in the Tikosyn Program by submitting to Pfizer a completed Institution Certification Form, and agreeing to the following:
  - 1. I attest that the healthcare facility where Tikosyn is initiated or re-initiated can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;
  - 2. I will ensure that all appropriate staff (including physicians, pharmacists, and telemetry nurses) are trained regarding the Tikosyn REMS program and will comply with all of the program requirements;
  - 3. I will establish or oversee the establishment of a system, order sets, protocols, or other measures to ensure appropriate dosing and monitoring;
  - 4. I will ensure that the pharmacy staff verifies that the prescribing healthcare provider is enrolled in the Tikosyn program prior to dispensing Tikosyn for inpatient use;
  - 5. I understand that, prior to patient discharge, the health care facility must either: provide a free 7-day (14-count) supply of Tikosyn and the Medication Guide to patients, or ensure the patient's take-home prescription is filled.
- ii. Each pharmacy where Tikosyn is dispensed will designate a representative. The designated representative will enroll in the Tikosyn Program by submitting to Pfizer a completed Tikosyn In Pharmacy Systems (T.I.P.S) Program Certification Form, agreeing to the following:
  - 1. I will ensure that all appropriate staff are trained and have read and understand the T.I.P.S. program materials.
  - 2. I will ensure that pharmacy staff will verify that the prescriber is certified in the Tikosyn program prior to dispensing each prescription, by accessing the system.
  - 3. I will ensure pharmacy staff stamp each prescription with the provided T.I.P.S. Stamp and initial and date the Tikosyn stamped prescription in the appropriate areas, verifying prescriber certification status.

- 4. I will ensure that the Medication Guide is provided by the pharmacy staff to the patient with each prescription.
- 5. I will ensure a copy of the above attestations is posted or otherwise made available to pharmacy staff to ensure that the pharmacy staff understands these special conditions for use of Tikosyn.
- b. A Tikosyn Stamp will be provided to certified Retail/Mail-order Pharmacies in the T.I.P.S materials sent to pharmacies after certification so that they will be able to stamp the prescription.
- c. Pfizer will require a one time re-certification of all currently certified health care facilities and pharmacies within 6 months after REMS approval.
- d. Within 30 days of the initial approval of the Tikosyn REMS, Pfizer will send Dear Pharmacist letters to all currently certified health care settings and pharmacies to notify them of the need to re-certify. The re-certification letter will reinforce the safety messages, safe use conditions, and REMS program elements. The letter will include a copy of the Tikosyn Full Prescribing Information, Medication Guide, Tikosyn Treatment Guidelines and Certification form, and will be available on the Tikosyn REMS program website for 6 months from the date of issuance of the letter.
- e. Pfizer will de-certify Tikosyn Program participant(s) for non-compliance, if warranted by assessments to evaluate compliance to Tikosyn Program requirements.
- f. The following materials are part of the REMS and are appended:
  - 1. Dear Pharmacist Letter for re-certification (Institution and Retail/Mail-order Pharmacies, as applicable)
  - 2. Dear Pharmacist Letter for new enrollees (Institution and Retail/Mail-order Pharmacies, as applicable)
  - 3. Tikosyn Program Treatment Guidelines
  - 4. Pharmacy Certification Form (Institution and Retail/Mail-order Pharmacies, as applicable)
  - 5. T.I.P.S. Program Kit
  - 6. Tikosyn REMS Website

# **C. Implementation System**

The Implementation System will include the following:

1. Pfizer will distribute Tikosyn only to certified prescribers, pharmacies, and health care settings.

- 2. Pfizer will maintain the Pfizer National Tikosyn Database, which includes the record of all enrolled and certified health care settings and pharmacies that dispense and prescribers who prescribe Tikosyn.
- 3. Pfizer will review distribution data to assess compliance with the requirements that Tikosyn only be dispensed by certified dispensers.
- 4. Pfizer will monitor compliance with the Tikosyn program to help ensure prescriptions are written by certified prescribers and that certified dispensers dispense Tikosyn in accordance with the program requirements, by conducting surveys of institutions and prescribers.
- 5. Based on the monitoring and evaluation of the implementation of the elements to assure safe use provided for under section B2, Pfizer will take reasonable steps to improve implementation of these elements and adherence to the REMS requirements to meet the goal of the REMS.

# **D.** Timetable for Submission of Assessments

Pfizer will submit REMS Assessments to the FDA at 6 months and 1 year from the date of the approval of the REMS, and annually thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Pfizer will submit each assessment so that it will be received by the FDA on or before the due date.



U.S. Pharmaceuticals

#### New FDA Requirement: Prescriber Certification Needed to Prescribe TIKOSYN<sup>®</sup> (dofetilide)

[Date]

Dear Dr [insert last name]:

**Per FDA requirements, in order to prescribe TIKOSYN, new prescribers are required to complete a one-time certification**. TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

The TIKOSYN Education Distribution Program, currently known as the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS), is required by the FDA to ensure safe use of TIKOSYN in order to mitigate the risk of induced arrhythmia by

- Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care
  facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and
  cardiac resuscitation;
- Informing patients about the serious risks associated with TIKOSYN therapy.

In order to become certified you must review the enclosed materials and sign the certification form. The materials include the following:

- TIKOSYN Treatment Guidelines
- Prescribing Information
- Medication Guide
- Prescriber Certification Form

When you have reviewed all the materials, **please sign and mail or fax back the certification form.** The fax number is (800)-788-2637. After we have received your certification form, we will send a written confirmation of receipt.

In addition to your certification, **retail pharmacies** and **institutional pharmacies** must also be certified in order to dispense TIKOSYN. Before dispensing a prescription for TIKOSYN, the pharmacist must confirm that you are a health care professional who has been certified and is listed in the Pfizer National TIKOSYN Database.

avoid any disruptions in their treatment. Although patients must be provided with TIKOSYN upon discharge, it may take a few business days for the pharmacy to order TIKOSYN for subsequent prescriptions.

Should you have any questions regarding the certification program, please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com.

Regards,

establishing M.O.

Robert Wolkow, MD, FAAFP Senior Medical Director/Team Leader U.S. Brands Established Products Business Unit TKU00124 ©2011 Pfizer Inc

All rights reserved



**U.S. Pharmaceutical**s

#### <u>New FDA Requirement:</u> <u>Prescriber Re-certification Required by November 2011 to Prescribe TIKOSYN<sup>®</sup> (dofetilide)</u>

May 2011

Dear Dr [insert last name]:

You previously completed the TIKOSYN Certification Requirement, which acknowledged that you reviewed TIKOSYN education material. Per FDA requirements, in order to continue to prescribe TIKOSYN, you are required to secure a one-time re-certification by November 2011.

TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

The TIKOSYN Education Distribution Program, currently known as the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS), is required by the FDA to ensure safe use of TIKOSYN in order to mitigate the risk of induced arrhythmia by

- Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care
  facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and
  cardiac resuscitation;
- Informing patients about the serious risks associated with TIKOSYN therapy.

In order to become recertified, you must review the enclosed materials and sign the certification form. The materials include the following:

- TIKOSYN Treatment Guidelines
- Prescribing Information
- Medication Guide
- Prescriber Certification Form

When you have reviewed all the materials, **please sign and mail or fax back the certification form.** The fax number is (800) 233-9141. After the certification form is received, you will receive written confirmation of receipt.

In addition to your re-certification, **retail pharmacies** and **institutional pharmacies** must also be certified. Before dispensing a prescription for TIKOSYN, the pharmacist must confirm that you are a health care professional who has been certified and is listed in the Pfizer National TIKOSYN Database.

It is important that you tell your patients to fill their TIKOSYN prescriptions as soon as possible after they are discharged to avoid any disruptions in their treatment. Although patients must be provided with TIKOSYN upon discharge, it may take a few business days for the pharmacy to order TIKOSYN for subsequent prescriptions.


Should you have any questions regarding the certification program, please call 866-249-7261 or visit www.TIKOSYNREMS.com.

Regards,

establishing M.O.

Robert Wolkow, MD, FAAFP Senior Medical Director/Team Leader TKU00124 ©2011 Pfizer Inc

All rights reserved



U.S. Brands Established Products Business Unit

TKU00124

©2011 Pfizer Inc

All rights reserved

# TIKOSYN<sup>®</sup> (dofetilide) TREATMENT GUIDELINES

These guidelines are part of the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS) program. Prescribers and Pharmacists are required to read these guidelines and sign a Certification Form acknowledging they understand the potential risks of TIKOSYN in order to prescribe and dispense TIKOSYN.

1

Below, you will find detailed treatment guidelines for TIKOSYN<sup>®</sup> (dofetilide). Please call 1-877-TIKOSYN if you need additional information.

## **Table of Contents**

Important Safety Information	Page 3
Dosing Overview	Page 4
Steps for Initiation and Dosing	Page 5
<ul> <li>Predose Steps</li> <li>Dosing</li> <li>Postdose Adjustments</li> <li>Actions Prior to Patient Discharge</li> </ul>	Page 5 Page 6 Page 6 Page 7

Patient Counseling

Page 8

2

#### **Important Safety Information**

TIKOSYN is indicated for the conversion and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

TIKOSYN is contraindicated with verapamil, with hydrochlorothiazide (alone or in combinations such as with triamterene), and with cation transport inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, and megestrol. (Alternatives to cimetidine include Maalox®, Prilosec®, and Zantac®.)

Warnings/Interactions: Inhibitors of the CYP3A4, renal cation transports, drugs that prolong the QT interval, and other antiarrhythmics may increase the risk of proarrhythmia either by increasing dofetilide exposure or by adding to its QT-prolonging effect.

Precautions/Interactions: The following should be coadministered with care as they might increase dofetilide levels: macrolide antibiotics, azole antifungal agents, protease inhibitors, selective serotonin reuptake inhibitors, amiodarone, cannabinoids, diltiazem, nefazodone, zafirlukast, norfloxacin, quinine, triamterene, metformin, amiloride, and grapefruit juice.


To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.

3

## **Dosing Overview**

# Please review this overview of dosing for TIKOSYN® (dofetilide).

Dosing Algorithm Used in the TIKOSYN Clinical Program



TIKOSYN [product information] New York, NY; Pfizer Inc.: 2004

4

## **Steps for Initiation and Dosing**

The following are suggested guidelines for the initiation and dosing of TIKOSYN<sup>®</sup> (dofetilide).

# PREDOSE STEPS

**1.** Before initiating TIKOSYN therapy, previous antiarrhythmic therapy should be withdrawn for a minimum of 3 plasma half-lives. TIKOSYN should not be initiated following amiodarone therapy until amiodarone plasma levels are below 0.3 mcg/mL or until amiodarone has been withdrawn for at least 3 months.

2. Patients with atrial fibrillation should be anticoagulated according to usual medical practice.

**3.** Admit patient to the telemetry unit; choose a telemetry lead with a visible QT interval. All measurements of the QT interval should be from this lead.

**4.** Telemetry monitoring should continue for a minimum of 3 days or for 12 hours after conversion to normal sinus rhythm, whichever is longer.

**5.** The concomitant use of verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), or the cation transport system inhibitors cimetidine, trimethoprim (alone or in combination with sulfamethoxazole), and ketoconazole with TIKOSYN is contraindicated, as each drug causes a substantial increase in dofetilide plasma concentration. In addition, other known inhibitors of the renal cation transport system, such as prochlorperazine and megestrol, should not be used in patients on TIKOSYN. Please see full prescribing information for TIKOSYN.

# 6. CAUTION should be used when coadministering TIKOSYN with macrolide antibiotics, azole antifungals, protease inhibitors, and SRIs, as these agents may increase blood levels of TIKOSYN.

**7.** Concomitant administration of TIKOSYN and digoxin is permitted. Carefully monitor patients for the signs and symptoms of digoxin toxicity. The concomitant administration of digoxin was associated with a higher occurrence of torsades de pointes. It is not clear whether this represents an interaction with TIKOSYN or the presence of more severe structural heart disease in patients taking digoxin.

8. If potassium (K+) is <4.0 mEq/L, replace K+ before administration of TIKOSYN.

**9.** Before administering the first dose of TIKOSYN on Day 1, measure the QTc interval (determine the QT if the heart rate is <60 bpm or >100 bpm).

- If baseline QTc is >440 msec (500 msec in patients with ventricular conduction abnormalities), TIKOSYN is **CONTRAINDICATED**; if ≤440 msec, you may proceed.
- Note time, date, and the telemetry lead on the strip.
- All measurements of the QTc interval should be from this lead.

**10.** Measure the QT interval (determine QTc) 2-3 hours after each dose of TIKOSYN until the patient is discharged.

- 11. Determine the patient's actual body weight in kg.
- **12.** Measure patient's serum creatinine level as mg/dL.

**13.** Calculate patient's creatinine clearance using the following formula:

Male creatinine clearance =	(140-age) x actual body weight in kg 72 x serum creatinine (mg/dL)
Female creatinine clearance =	(140-age) x actual body weight in kg x 0.85 72 x serum creatinine (mg/dL)

## **DOSING**

**14.** The creatinine clearance results should be received by the pharmacy to dispense the first TIKOSYN<sup>®</sup> (dofetilide) dose.

15. If the calculated creatinine clearance is <20 mL/min, TIKOSYN is CONTRAINDICATED.

16. If the calculated creatinine clearance is >60 mL/min, the appropriate dose of TIKOSYN is 500 mcg BID.

• 2-3 hours after the **initial dose**, if QTc increases to >15% from baseline, then decrease TIKOSYN to 250 mcg BID.

**17.** If the calculated creatinine clearance is between 40 mL/min and 60 mL/min, the appropriate dose of TIKOSYN is 250 mcg BID.

- 2-3 hours after the **initial dose**, if QTc increases to >15% from baseline, then decrease TIKOSYN to 125 mcg BID.
- If QTc increases to >500 msec (550 msec in the presence of a ventricular conduction abnormality), TIKOSYN should be decreased to 125 mcg BID.

**18.** If the calculated creatinine clearance is 20 mL/min to <40 mL/min, the appropriate dose of TIKOSYN is 125 mcg BID.

- >2-3 hours after the **initial dose**, if QTc increases to >15% from baseline, then decrease TIKOSYN to 125 mcg QD.
- If QTc increases to >500 msec (550 msec in the presence of a ventricular conduction abnormality), then decrease TIKOSYN to 125 mcg QD.

## POSTDOSE ADJUSTMENTS

**19.** The **second dose** of TIKOSYN should only be given after the QT has been determined. Only 1 down titration of TIKOSYN for QTc is suggested. If QTc is still excessively prolonged, DISCONTINUE TIKOSYN therapy.

**20.** During therapy initiation in the hospital, at 2-3 hours after each dose of TIKOSYN, determine the QTc to see if dose adjustment is necessary.

6

- Response to QT measurement after the **first dose**:
  - If QTc increases by >15% or is >500 msec (550 msec in the presence of a ventricular conduction abnormality), decrease the TIKOSYN<sup>®</sup> (dofetilide) dose as described above.
- Response to QT measurement after subsequent doses:
  - If after subsequent doses the QTc is >500 msec (550 msec in the presence of a ventricular conduction abnormality), TIKOSYN should be DISCONTINUED.

**21.** TIKOSYN should be given q12h (actual times may vary according to local hospital practice; the doses should be given at the same time each day, ie, 12 hours apart); QD TIKOSYN should be given at the same time every day. The risk of torsades de pointes is related to dose as well as to patient characteristics. Physicians may, therefore, in some cases, choose doses lower than determined by the algorithm. If at any time this lower dose is increased, the patient needs to be rehospitalized for 3 days. Previous toleration of higher doses does not eliminate the need for rehospitalization.

**22.** After the third TIKOSYN dose, discuss with patient the option of filling Rx with patient's mail-order or retail pharmacy. Both the mail-order and retail pharmacy must be enrolled in the T.I.P.S. program. The physician who orders a TIKOSYN prescription must be a confirmed participant of a TIKOSYN education program. You will need the patient's final dose of TIKOSYN, patient's full name (correct spelling), address, insurer, and physician's name. If the TIKOSYN dose is changed or discontinued after the prescription has been faxed, please notify the mail-order or retail pharmacy immediately.

The T.I.P.S.<sup>™</sup> Program is designed to allow retail pharmacies to stock and dispense TIKOSYN once they have been enrolled. Please visit www.TIKOSYNREMS.com for T.I.P.S.<sup>™</sup> enrollment information.

**23.** Contact your hospital pharmacy to order a TIKOSYN bottle with 14 capsules of the final dosage strength.\* The patient should be discharged with this bottle to ensure a sufficient drug supply for uninterrupted dosing until the patient receives the first outpatient supply of medication. Patient will be directed to fill prescription as soon as possible, since pharmacy may not have TIKOSYN stocked and requires at least 24 hours to fill prescription.

\*This bottle is supplied free of charge to hospitals.

# ACTIONS PRIOR TO PATIENT DISCHARGE

24. Ensure the patient received the TIKOSYN discharge bottle with 14 capsules.

25. Review the Medication Guide with your patient.

**26.** Alert patients that blood work and ECG will be re-evaluated every 3 months by their doctor to check the renal function and the QTc.

• If QTc exceeds 500 msec (550 msec in patients with ventricular conduction abnormalities), TIKOSYN therapy should be discontinued and patients should be carefully monitored until QTc returns to baseline levels. If renal function deteriorates, adjust dose as described in steps 16-18 under "Dosing Overview."

27. Inform the patient's Healthcare Professional that the patient is now on TIKOSYN<sup>®</sup> (dofetilide). Important points to mention include:

- TIKOSYN is contraindicated with verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), and cation transport inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, and megestrol.
- Renal function and OTc should be re-evaluated every 3 months or as medically warranted. •
- TIKOSYN is available through a mail-order or retail pharmacy enrolled in the T.I.P.S. program. If the Healthcare Professional would like to write a refill for the patient, he or she must be a confirmed participant in a TIKOSYN REMS program before the mail-order or retail pharmacy can fill the prescription. The Healthcare Professional can learn how to do this by calling 1-877-TIKOSYN (845-6796). Alternatively, the Healthcare Professional can continue to see the patient in consultation with a physician who is a confirmed participant in a TIKOSYN REMS program.
- On receipt of patient information, the Healthcare Professional should read the enclosed package • insert for more information. The most serious side effect of TIKOSYN is torsades de pointes. The most common side effects with TIKOSYN occurred at rates similar to placebo and included headache, chest pain, and dizziness.

# **Patient Counseling**

28. Advise your patients to:

- Read the Medication Guide every time they receive their prescription, including refills
- Not take cimetidine, verapamil, ketoconazole, trimethoprim/sulfamethoxazole, • hydroclorothiazide, prochlorperazine, or megestrol
- Tell you of all medications they are taking including prescription, non-prescription, natural/herbal • remedies, and vitamins or dietary supplements
- Report symptoms associated with electrolyte imbalance, including excessive or prolonged diarrhea, sweating, vomiting, or loss of appetite or thirst
- Not miss doses or take extra doses of TIKOSYN
- Not start any other medications, including OTCs without first consulting their doctor
- Get prescriptions filled and refilled as soon as possible to avoid any disruptions in treatment
- Report any adverse events •

TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.

For full prescribing information, please visit www.TIKOSYNREMS.com.

8

# TIKOSYN<sup>®</sup> (dofetilide) Prescriber Certification Form

D	0	C	u	m	e	n	t	N	u	m	

Your Name       Address 1         Address 2	Part Part P	<u>rimary</u>	<u> </u>	<u>CEINF</u>	<u> </u>		ON (Pleas	se print.	. All i	nformatior	n require	ed.)		
Address 2         City         State       Zip         Professional       MD       DO       PA       NP         YOUR WORK PHONE       YOUR OFFICE FAX NUMBER       YOUR EMAIL ADDRESS         PRIMARY DEA NUMBER       If you do not have a DEA #, you must provide your state iscense #. If you have both, please provide both.       PRIMARY STATE LICENSE NUMBER         PLEASE LIST ALL OTHER DEA NUMBER       If you have more than a check in the box at the left       STATE       Please print your tertiary state license number and state in the space provide the left         POURTH DEA NUMBER       If you have more than a check in the box at the left       STATE       Please print your tertiary state license number and state in the space provided         In case you are efficiated with one or more hospitals, please fill in the information       In case you are efficiated with one or more hospitals, please fill in the information below, starting with your primary. If more than dadress Line 1       Address Line 2         City       State       Zip       ThiRD         Hospital Name       Address Line 1       Address Line 2         City       State       Zip       ThiRD         Hospital Name       Address Line 1       Address Line 2         City       State       Zip       ThiRD         Hospital Name       Address Line 2       ThiRD	Your Name													
City Siste Zip Professional Designation: D D PA P P VOUR EMAIL ADDRESS PRIMARY DEA NUMBER VOUR WORK PHONE VOUR OFFICE FAX NUMBER VOUR CALL ADDRESS PRIMARY DEA NUMBER Hy ou do not have a DEA #, you must provide your state Remote that the location of the pace provide both. PRIMARY STATE LICENSE NUMBER SECOND DEA NUMBER Hy ou do not have a DEA #, you must provide your state PRIMARY STATE LICENSE NUMBER SECOND DEA NUMBER Hy ou do not have a DEA #, you must provide your state PRIMARY STATE LICENSE NUMBER THIRD DEA NUMBER Hy ou have both, please provide both. POURTH DEA NUMBER THIRD DEA NUMBER Hy ou have more than C D DEA Fs, please put a check in the box at the left Number and state in the space provide Hospital Affiliation Information D D D D D D D D D D D D D D D D D D D	Address 1													
City Siste Zip Professional Designation: D D PA P P VOUR EMAIL ADDRESS PRIMARY DEA NUMBER VOUR WORK PHONE VOUR OFFICE FAX NUMBER VOUR CALL ADDRESS PRIMARY DEA NUMBER Hy ou do not have a DEA #, you must provide your state Remote that the location of the pace provide both. PRIMARY STATE LICENSE NUMBER SECOND DEA NUMBER Hy ou do not have a DEA #, you must provide your state PRIMARY STATE LICENSE NUMBER SECOND DEA NUMBER Hy ou do not have a DEA #, you must provide your state PRIMARY STATE LICENSE NUMBER THIRD DEA NUMBER Hy ou have both, please provide both. POURTH DEA NUMBER THIRD DEA NUMBER Hy ou have more than C D DEA Fs, please put a check in the box at the left Number and state in the space provide Hospital Affiliation Information D D D D D D D D D D D D D D D D D D D	Address 2													
State         Zip         Prefersional Designation:         MD         DO         PA         NP           YOUR WORK PHONE         YOUR OFFICE FAX NUMBER         YOUR EMAIL ADDRESS         PRIMARY STATE LICENSE NUMBER         PRIMARY STATE LICENSE NUMBER           PRIMARY DEA NUMBER         If you do not have a DEA #, you must provide your state license #. If you have both, please privide both.         PRIMARY STATE LICENSE NUMBER           PLEASE LIST ALL OTHER DEA NUMBER         If you have more than four DEA #s, please put a state license numbers if you do not have a DEA #)         STATE         Please print your secondary state license number and state in the space provided           THIRD DEA NUMBER         If you have more than four DEA #s, please put a state in the space provided         STATE         Please print your secondary state license number and state in the space provided           Hasptal Atfillation Information         In case you are affiliated with one or more hospitals, please fill in the information below, starting with your primary. If more than afdress line 1         Address Line 2           Gity         State         Zip         City         State         Zip           Pfloar will ensure that healthcare providers who prescriber TKICSYN are specially certified. To become cartified, each prescriber will ensure that healthcare facilit the can provide calculations of oregular dearmace, continuose detrocardiographic monitoring, and cardinac resolutation.														
Note       Note       Note       Your end of the second	City													
PRIMARY DEA NUMBER       If you do not have a DEA #, you must provide your state       PRIMARY STATE LIGENSE NUMBER         PLEASE LIST ALL OTHER DEA NUMBERS (or additional state license numbers if you do not have a DEA #)       State       The second provide your state       State       The second provide your state       State       The second provide your state       State       State       State       State       Zip       The second provide your primary. If more than formation       State       Zip       State       Zip       City       S	State	Zip					DO P							
Iterase #. If you have both, please provide both.         PLEASE LIST ALL OTHER DEA NUMBERS (or additional state license numbers if you do not have a DEA #)         SECOND DEA NUMBER         If you have more than four DEA #s, please put a check in the box at the lot         POURTH DEA NUMBER         POURTH DEA NUMBER         If you have more than four DEA #s, please put a check in the box at the lot         In case you are affiliated with one or more hospitals, please fill in the information a check in the box at the let.         Hospital Name         Address Line 1         Address Line 2         City       State         City       State         Pficar will ensure that healthcare providers who prescriber CHRIGEN showing the transmit initiation or initiate on TIKOSYN are specially certified. To become certified, each prescriber will one in the program by submitting to Pizer a completed Prescriber Certification Form and agreeing to the following: <ul> <li>understand that platients initiated or TIKOSYN should be as per thi TIKOSYN label will cerease the risk of TIKOSYN-induced arrhythmia.</li> <li>will provider that TIKOSYN bia is associated with the risk of induced arrhythmias.</li> <li>will provide that TIKOSYN Medication Garding regulated for a minimum of 3 days to a healthcare facility the contents of the Medication Guide with each patient.</li> <li>will provide the TIKOSYN Medication Garding resuscitation.</li> <li>will provide that TIKOSYN Medication Garding resuscitation.</li> <li>will more more platents that TIKOSYN is associated with the risk of in</li></ul>	YOUR W	ORK PHONE		Y	OUR OFFIC	CE FA	X NUMBER			YOL	JR EMAI	L ADDRESS		
Iterase #. If you have both, please provide both.         PLEASE LIST ALL OTHER DEA NUMBERS (or additional state license numbers if you do not have a DEA #)         SECOND DEA NUMBER         If you have more than four DEA #s, please put a check in the box at the lot         POURTH DEA NUMBER         POURTH DEA NUMBER         If you have more than four DEA #s, please put a check in the box at the lot         In case you are affiliated with one or more hospitals, please fill in the information a check in the box at the let.         Hospital Name         Address Line 1         Address Line 2         City       State         City       State         Pficar will ensure that healthcare providers who prescriber CHRIGEN showing the transmit initiation or initiate on TIKOSYN are specially certified. To become certified, each prescriber will one in the program by submitting to Pizer a completed Prescriber Certification Form and agreeing to the following: <ul> <li>understand that platients initiated or TIKOSYN should be as per thi TIKOSYN label will cerease the risk of TIKOSYN-induced arrhythmia.</li> <li>will provider that TIKOSYN bia is associated with the risk of induced arrhythmias.</li> <li>will provide that TIKOSYN Medication Garding regulated for a minimum of 3 days to a healthcare facility the contents of the Medication Guide with each patient.</li> <li>will provide the TIKOSYN Medication Garding resuscitation.</li> <li>will provide that TIKOSYN Medication Garding resuscitation.</li> <li>will more more platents that TIKOSYN is associated with the risk of in</li></ul>														
SECOND DEA NUMBER       If you have more than four DEA is, please put the lest       Image: state in the space provided         FUIRT DEA NUMBER       Image: state in the box at the lest       Image: state in the space provided         FOURTH DEA NUMBER       Image: state in the box at the lest       Image: state in the space provided         Image: state in the box at the lest       Image: state in the box at the lest       Image: state in the box at the lest         Image: state in the box at the lest       Image: state in the box at the lest       Image: state in the box at the lest         Address Line 1       Address Line 2       Image: state in the state in	PRIMARY DEA	NUMBER						our state		PRIMARY	( STATE	LICENSE NU	IMBE	
THIRD DEANUMBER       If you have mont than four DEA fs, please put a check in the box at the left       Inumber and state in the space provided         FOURTH DEA NUMBER       If you have mont than four DEA fs, please put a check in the box at the left       STATE       Please print your tertiary state license number and state in the space provided         Image: State	PLEASE LIST A	ALL OTHER I	DEA NUM	IBERS (or	r addition	nal s	tate licens	e num	oers	if you do	not ha	ve a DEA	#)	
THIRD DEA NUMBER       If you have more than be infor DEA is please put a check in the box at the left         FOURTH DEA NUMBER       If our DEA is please put a check in the box at the left         Image: Interpret A	SECOND DEA	NUMBER					ST							
FOURTH DEA NUMBER         In four DEA is, please put the left         STATE       Please print your tertiary state license number and state in the space provided         Hospital Affiliation Information         In case you are affiliated with one or more hospitals, please fill in the information below, starting with your primary. If more than for affiliations, put a check in the box at the left.         Respital Name         Address Line 1         Address Line 2         City       State       Zip         THIRD         Hospital Name         Address Line 2         City       State       Zip         THIRD         Hospital Name         Address Line 2         City       State       Zip         THIRD         Hospital Name         Address Line 2         City       State       Zip         Other will ensure that healthcare providers who prescribe TiKOSYN are pocially certified. To become certified, each prescriber will enritication form and agreeing to the following: <th colsp<="" td=""><td></td><td></td><td></td><td>If you hav</td><td>e more thar</td><td>n</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></th>	<td></td> <td></td> <td></td> <td>If you hav</td> <td>e more thar</td> <td>n</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>				If you hav	e more thar	n							
FOURTH DEA NUMBER       a curred and the BOX and the left.         Image: the left       image: the left         Image: the left       image: the left <td></td> <td>OMDEN</td> <td></td> <td>four DEA</td> <td>#s, please p</td> <td>put</td> <td></td> <td></td> <td>Disa</td> <td></td> <td></td> <td>atota llasses</td> <td></td>		OMDEN		four DEA	#s, please p	put			Disa			atota llasses		
Hospital Affiliation Information         In case you are affiliated with one or hospitals, please fill in the information below, starting with your primary. If more than for affiliations, put a check in the box at the left.         PRIMARY       SECOND         Hospital Name       Address Line 1         Address Line 2       City       State       Zip         THIRD       FOURTH       Address Line 2       City       State       Zip         Address Line 2       City       State       Zip       City       State       Zip         Plizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enring the rogram by submitting to Plizer a completed Prescriber Certification Form and agreeing to the following:       I understand that platients initiated or re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facilit that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.       I understand that platients that TIKOSYN is associated with the risk of induced arrhythmias.         I will inform up patients that TIKOSYN is associated with the risk of induced arrhythmias.       I will inform up patients that TIKOSYN is associated with the risk of induced arrhythmias.         I will inform up patients that TIKOSYN is associated with the risk of induced arrhythmia.       I will inform up patients that TIKOSYN is associated with the risk of induced arhythmias.         I will inform up patien	FOURTH DEA	NUMBER			1 the box at									
In case you are affiliated with one or more hospitals, please fill in the information below, starting with your primary. If more than for affiliations, put a check in the box at the lett.				-										
In case you are affiliated with one or more hospitals, please fill in the information below, starting with your primary. If more than the affiliations, put a check in the box at the lett.				Hc	ospita <u>l Affili</u>	iatior	n Information							
Affiliations, put a check in the box at the left.		are affiliated wit	th one or m		•				star	ing with vo	ur prima	ry. If more th	an fe	
PRIMARY       SECOND         Hospital Name       Address Line 1         Address Line 2					, pieuse II			511 DEIOW	, star					
Hospital Name       Address Line 1         Address Line 2       Address Line 2         City       State       Zip         THIRD       FOURTH         Hospital Name       Address Line 1         Address Line 1       Address Line 2         City       State       Zip         FOURTH       Hospital Name         Address Line 1       Address Line 1         Address Line 2       Address Line 2         City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enrint in the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:         I understand that plotents in initiated on TKOSYN should be admitted for a minimum of 3 days to a healthcare facilit that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         I will inform my patients that TIKOSYN Medication Guide to each patient at the initiation and re-initiation of TIKOSYN therapy. I will review the contents of the Medication Guide with each patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN under this progra										SECON	n			
Address Line 1         Address Line 2         City       State       Zip         THIRD       FOURTH         Hospital Name       Address Line 2         Address Line 2       City       State       Zip         City       State       Zip       City       State       Zip         Address Line 2       City       State       Zip       City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enrini the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:       I understand that patients initiated or re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facilit that can provide calculations of creatinine clearance, continuous electrocardiographic mominum, and calca resuscritan.         I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN induced arrhythmia.         I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmia.         I will inform my patients that TIKOSYN are clease the patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN educational materials. I understand this information will be used to enable Pfizer to identify	Lie en its i bi-	PRIM	ARY				He cost in the			SECON				
Address Line 2       Address Line 2         City       State       Zip         THIRD       FOURTH         Hospital Name       Address Line 1         Address Line 2       City       State       Zip         City       State       Zip       Address Line 1         Address Line 2       City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enrine the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:       I understand that patients initiated or re-initiated on TIKOSYN are specially certified. To become certified, each prescriber will enrine that a provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         • I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN induced arrhythmia.         • Will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         • I will provide the TIKOSYN Medication Guide to each patient at the initiation of TIKOSYN educational materials. I understand that following the each patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN educational materials. I understand the TIKOSYN under this program I understand Pfizer might share this information with others acting on its behalf and/or prescriber TIKOSYN under this program I understand Pfizer mig	-													
City       State       Zip         Hospital Name       Address Line 1       Address Line 1       Address Line 1         Address Line 2       City       State       Zip         City       State       Zip       City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TKOSYN are specially certified. To become certified, each prescriber will enrinit the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:       I city       State       Zip         Pfizer will ensure that healthcare providers who prescriber Certification Form and agreeing to the following:       I understand that patients initiated on TI-KOSYN should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia.         I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmia.         I will provide the TIKOSYN Medication Guide to each patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN under this prograf I understand Pfizer might share this information with others acting on its behalf and/or government agencies.         Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or wistwwwithCROSYN should be pla							Address Line	e 1						
FOURTH         Hospital Name       Address Line 1         Address Line 2       Address Line 2         City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enrino in the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:         • I understand that patients initiated or re-initiated on TIKOSYN should be adminum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         • I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia.         • Will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         • Will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         • Will inform my patients that TIKOSYN Medication Guide to each patient at the initiation and re-initiation of TIKOSYN therapy. I will review the contents of the Medication Guide with each patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN educational materials. I understand this information with others acting on its behalf and/or government agencies.         I understand Pfizer might share this information with others acting on its behalf and/or government agencies.       TicoSYN         Prescriber Signature       Date	Address Line 2							-						
Hospital Name       Hospital Name         Address Line 1       Address Line 2         City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enrine the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:         • I understand that patients initiated on re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         • I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         • I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmia.         • I will provide the TIKOSYN Medication Guide to each patient at the initiation and re-initiation of TIKOSYN therapy. I will review the contents of the Medication Guide to each patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN under this program I understand Pfizer might share this information with others acting on its behalf and/or government agencies.         Prescriber Signature       Date         Please main or fax this document to: TIKOSYN educed arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitorin		1		1				e 2				T		
Address Line 1       Address Line 1         Address Line 2       Address Line 2         City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enrin the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:         •       I understand that patients initiated or reinitiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         •       I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia.         •       I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         •       I will inform my patients that their blood lab measures and ECG should be reevaluated every 3 months.         •       I will inform my patients that their blood lab measures and ECG should be reevaluated every 3 months.         •       I will provide the TIKOSYN Medication Guide to each patient at the initiation on TIKOSYN houre this program lip or idea to anable Pfizer to identify prescribers who are eligible to initiate and/or prescribe TIKOSYN Muter this program lip understand that file on the decication will be used to enable Pfizer to identify prescribers who are eligible to initiate and/or government agencies.         Please retain a copy of this form for your records.       For any questions please cal	City	· · · ·		Zip				e 2				Zip		
Address Line 2       Address Line 2         City       State       Zip         Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enring the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:         • I understand that patients initiated or re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.         • I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia.         • I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.         • I will inform my patients that The blood lab measures and ECG should be reevaluated every 3 months.         • I will inform my patients that their blood lab measures and ECG should be reevaluated every 3 months.         • I will inform my patients that the is of induced arrhythmias.         • I will inform my patients that the above information is correct. I confirm that I have read and understand the TIKOSYN therapy. I will review the contents of the Medication Guide to each patient.         I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN under this program I understand Pfizer might share this information with others acting on its behalf and/or government agencies.         Prescriber Signature       Date         Prease retain a c		· · · ·		Zip			City	-			H	Zip		
City         State         Zip         City         State         Zip           Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enring the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following:         I understand that patients initiated or re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.           I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia.         I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.           I will inform my patients that TIKOSYN Medication Guide to each patient at the initiation and re-initiation of TIKOSYN therapy. I will review the contents of the Medication Guide with each patient.           I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN educational materials. I understand this information will be used to enable Pfizer to identify prescribers who are eligible to initiate and/or prescribe TIKOSYN under this progra I understand Pfizer might share this information with others acting on its behalf and/or government agencies.           Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com.         For any questions please call 1-877-TIKOSYN or visit www.TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic m	Hospital Name	· · · ·		Zip			City Hospital Nar	me			н	Zip		
Pfizer will ensure that healthcare providers who prescribe TIKOSYN are specially certified. To become certified, each prescriber will enr in the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following: • I understand that patients initiated or re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. • I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia. • I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias. • I will provide the TIKOSYN Medication Guide to each patient at the initiation and re-initiation of TIKOSYN therapy. I will review the contents of the Medication Guide to each patient. I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN educational materials. I understand this information will be used to enable Pfizer to identify prescribers who are eligible to initiate and/or prescribe TIKOSYN under this progra I understand Pfizer might share this information with others acting on its behalf and/or government agencies. Prescriber Signature Date Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNEEMS.com. Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNEEMS.com. To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education	Hospital Name Address Line 1	· · · ·		Zip			City Hospital Nar Address Line	me e 1			H	Zip		
in the program by submitting to Pfizer a completed Prescriber Certification Form and agreeing to the following: <ul> <li>I understand that patients initiated or re-initiated on TIKOSYN should be admitted for a minimum of 3 days to a healthcare facilit that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation.</li> <li>I understand that following the treatment initiation and dosing guidelines as per the TIKOSYN label will decrease the risk of TIKOSYN-induced arrhythmia.</li> <li>I will inform my patients that TIKOSYN is associated with the risk of induced arrhythmias.</li> <li>I will inform my patients that their blood lab measures and ECG should be reevaluated every 3 months.</li> <li>I will provide the TIKOSYN Medication Guide to each patient at the initiation and re-initiation of TIKOSYN therapy. I will review the contents of the Medication Guide with each patient.</li> </ul> I confirm that the above information is correct. I confirm that I have read and understand the TIKOSYN educational materials. I understand this information will be used to enable Pfizer to identify prescribers who are eligible to initiate and/or prescribe TIKOSYN under this program I understand Pfizer might share this information with others acting on its behalf and/or government agencies. Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com. Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com. To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initia	Hospital Name Address Line 1	· · · ·					City Hospital Nar Address Line	me e 1			H			
this information will be used to enable Pfizer to identify prescribers who are eligible to initiate and/or prescribe TIKOSYN under this progra I understand Pfizer might share this information with others acting on its behalf and/or government agencies. Prescriber Signature Date Please mail or fax this document to: TIKOSYN Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com. To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education	Hospital Name Address Line 1 Address Line 2 City Pfizer will ensure	THII State	RD	<b>Zip</b>			City Hospital Nar Address Line Address Line City specially cer	me e 1 e 2 rtified. To		FOURT	d, each p	Zip	ll enr	
Please retain a copy of this form for your records. For any questions please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com. PO Box 2147 Morrisville, PA 19067-0647 FAX (800) 233-9141 To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education	Hospital Name Address Line 1 Address Line 2 City Pfizer will ensure in the program by • I understan that can pre • I understan TIKOSYN-i • I will inform • I will inform • I will inform	THII State that healthcare v submitting to l ad that patients ovide calculation ad that following induced arrhyth n my patients th n my patients th de the TIKOSYN	Providers w Pfizer a com initiated or ons of creati g the treatmonia. nat TIKOSYN nat their bloc Medicatior	<b>Zip</b> who prescrib pleted Pres re-initiated nine clearar ent initiatior N is associa od lab meas n Guide to e	scriber Cert on TIKOSY nce, continu n and dosin ted with the sures and E each patient	tificat 'N sh uous ng gu e risk :CG s	City Hospital Nar Address Line Address Line City specially cer tion Form and ould be admi electrocardid idelines as per to finduced a should be ree	me e 1 e 2 rtified. To d agreein itted for a ographic er the TIP arrhythmi evaluated	ig to t a mini Moni KOSY ias.	FOURT State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State	d, each p g: ays to a cardiac r decreas	Zip prescriber wi healthcare f resuscitation e the risk of	acilit <u></u>	
To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education	Hospital Name Address Line 1 Address Line 2 City Pfizer will ensure in the program by I understan that can pre I understan TIKOSYN-i I will inform I will inform I will provid the content I confirm that the this information w	THII State that healthcare v submitting to l ad that patients ovide calculation of that following induced arrhyth a my patients the amy patients the the TIKOSYN ts of the Medica above informativill be used to er	RD providers w Pfizer a com initiated or ons of creati g the treatm mia. nat TIKOSYN nat their bloc Medicatior ation Guide <i>ion is correc</i> <i>nable Pfizer</i>	<b>Zip</b> who prescrib npleted Pres re-initiated nine clearar ent initiation N is associa od lab meas n Guide to e with each p ct. I confirm to identify p	scriber Cert on TIKOSY nce, continu n and dosin ted with the sures and E each patient patient. that I have r prescribers v	tificat N sh uous ng gu e risk CG s t at th read	City Hospital Nar Address Line Address Line City specially certion Form and ould be admi electrocardid idelines as point and induced a should be ree he initiation a and understa are eligible to	me e 1 e 2 rtified. To d agreein itted for a ographic er the TIP arrhythmi evaluated and re-ini md the TI initiate a	ig to t a mini Moni (OSY ias. ever tiation tiation	FOURT	d, each p g: ays to a cardiac r decreas 'N therap nal mate	<b>Zip</b> prescriber wi healthcare f resuscitation e the risk of py. I will revie rials. I unders	acilit <u></u> w	
	Hospital Name Address Line 1 Address Line 2 City Pfizer will ensure in the program by I understan that can pre- I understan TIKOSYN-i I will inform I will inform I will provid the content I confirm that the this information w I understand Pfized Please retain a copy For any questions play	THII State that healthcare v submitting to I ad that patients ovide calculation ad that following induced arrhyth a my patients the de the TIKOSYN ts of the Medica above informativit vill be used to er or might share the of this form for yo ease call 1-877-TI	RD providers w Pfizer a com- initiated or ons of creating the treatmo- mia. mat TIKOSYN mat their block Medication ation Guide ion is correct nable Pfizer his information uur records.	<b>Zip</b> who prescrib npleted Pres re-initiated nine clearar ent initiation N is associa od lab meas n Guide to e with each p ct. I confirm to identify p	scriber Cert on TIKOSY nce, continu n and dosin ted with the sures and E each patient patient. that I have r prescribers v	tificat N sh uous ng gu e risk CG s t at th read	City Hospital Nar Address Line Address Line City specially cer tion Form and ould be admi electrocardic idelines as pr to of induced a should be ree he initiation a and understa are eligible to behalf and/or	me e 1 e 2 rtified. To d agreein itted for a ographic er the TIk arrhythmi evaluated and re-ini initiate ar governm criber S Please	ag to t a mini moni (OSY) ias. ever tiation <i>KOSY</i> <i>md/or</i> <i>ment a</i> <i>i</i> gna <i>a</i> mail	FOURT State me certified he following mum of 3 d toring, and 0 N label will / 3 months. n of TIKOSY /N education prescribe T gencies. ture or fax this TIKOSYN PO Box 214 ville, PA 190	d, each p g: ays to a cardiac r decreas 'N therap <i>nal mate</i> <i>IKOSYN</i> D docume	<b>Zip</b> prescriber wi healthcare f resuscitation e the risk of oy. I will revie rials. I unders under this pr ate ent to:	acilit <u></u> w	



U.S. Pharmaceuticals

#### <u>New FDA Requirement:</u> Institution Certification Needed to Order, Stock, and Dispense TIKOSYN<sup>®</sup> (dofetilide)

[Date]

Dear Dr. [insert last name]:

Per FDA requirements, in order to order, stock, and dispense TIKOSYN, new pharmacies are required to secure a one-time certification. TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

The TIKOSYN Education Distribution Program, currently known as the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS), is required by the FDA to ensure safe use of TIKOSYN in order to mitigate the risk of induced arrhythmia by

- Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care
  facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and
  cardiac resuscitation;
- Informing patients about the serious risks associated with TIKOSYN therapy.

To order, stock, and dispense TIKOSYN, you must review and follow the TIKOSYN certification procedures. This will acknowledge that you, along with the appropriate staff in the institution, have been trained regarding the TIKOSYN REMS program. In order to become certified, you must review the enclosed materials and sign the certification form. The materials include the following:

- TIKOSYN Treatment Guidelines
- Prescribing Information
- Medication Guide
- Institution Certification Form

Before dispensing TIKOSYN, the pharmacist is required to confirm that the prescriber has been certified. In addition, the institution must agree to stock and provide patients prior to discharge a free 7-day (14 count) supply of TIKOSYN and the Medication Guide. As a contingency, if the initiating/re-initiating institution does not have outpatient licensing privileges to dispense the free 7-day supply of TIKOSYN, the institution will ensure the patient's take home prescription is ordered and filled at a retail pharmacy prior to patient discharge.

When you have reviewed all the materials, **please sign and mail or fax back the certification form.** The fax number is 800-788-2637. After the certification form is received, you will receive written confirmation of receipt. In addition, before dispensing TIKOSYN, you are required to confirm that the prescriber has been certified.

Should you have any questions regarding the certification program, please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com.

Regards,

le Mollow no

Robert Wolkow, MD, FAAFP Senior Medical Director/Team Leader U.S. Brands TKU00126 ©201

©2011 Pfizer Inc

All rights reserved



#### Established Products Business Unit

TKU00126

©2011 Pfizer Inc



**U.S. Pharmaceuticals** 

#### New FDA Requirement:

#### Institution Re-certification by November 2011 Needed to Order, Stock and Dispense TIKOSYN® (dofetilide)

May 2011

Dear Dr. [insert last name]:

You previously completed the TIKOSYN Certification Requirement, which acknowledged that you reviewed the TIKOSYN education materials and that the appropriate staff in the institution had been trained regarding the TIKOSYN REMS program. Per FDA requirements, in order to continue to order, stock, and dispense TIKOSYN you are required to secure a one-time re-certification by November 2011.

TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

The TIKOSYN Education Distribution currently known as the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS), is required by the FDA to ensure safe use of TIKOSYN in order to mitigate the risk of induced arrhythmia by

- Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;
- Informing patients about the serious risks associated with TIKOSYN therapy.

In order to become recertified, you must review the enclosed materials and sign the certification form. The materials include the following:

- TIKOSYN Treatment Guidelines
- Prescribing Information
- Medication Guide
- Institution Certification Form

Before dispensing TIKOSYN, the pharmacist is required to confirm that the prescriber has been certified. In addition, the institution must agree to stock and provide patients prior to discharge a free 7-day (14 count) supply of TIKOSYN and the Medication Guide. As a contingency, if the initiating/re-initiating institution does not have outpatient licensing privileges to dispense the free 7-day supply of TIKOSYN, the institution will ensure the patient's take home prescription is ordered and filled at a retail pharmacy prior to patient discharge.

When you have reviewed all the materials **please sign and mail or fax back the certification form.** The fax number is (800) 233-9141. After the certification form is received, you will receive written confirmation of receipt. In addition, before dispensing TIKOSYN, you are required to confirm that the prescriber has been certified.

Should you have any questions regarding the certification program, please call (866) 249-7261 or visit www.TIKOSYNREMS.com.

Regards,

establishing M.O.

Robert Wolkow, MD, FAAFP Senior Medical Director/Team Leader U.S. Brands

TKU00126

©2011 Pfizer Inc

All rights reserved



#### Established Products Business Unit

TKU00126

©2011 Pfizer Inc

# **TIKOSYN®** (dofetilide) Institution Certification Form

A designated representative must complete and sign this form as part of the TIKOSYN REMS requirements.

PRIM	APY INSTIT	UTION INFORMATION (Please print. All information required.)
Designated Representa		
Title/Position		
Institution Name	<u> </u>	
Address 1	1	
Address 2	t	
City	1	
State	Zip	
YOUR WOR	KK PHONE	YOUR OFFICE FAX NUMBER YOUR EMAIL ADDRESS
	!	
I DES	IGNATE THE FOLLOV	WING AFFILIATED IN-HOSPITAL PHARMACIES, IDENTIFIED BY DEA NUMBER(S) UNDER THIS AUTHORIZATION
		PLEASE LIST THE DEA #(S) COVERED BY THIS AGREEMENT
		DEA NUMBER(S)
	L	
in the TIKOSYN Prog I attest that the continuous ele I will ensure the REMS program I will establish and monitorir I will ensure the dispensing TIH I understand the and the Medic	ogram by submitting to he healthcare facility w lectrocardiographic mo that all appropriate stat am and will comply with sh or oversee the estab- ing. that the pharmacy staff IKOSYN for inpatient u that, prior to patient d ication Guide to patien	is dispensed for use will designate a representative. The designated representative will enroll o Pfizer a completed Institution Certification Form and agreeing to the following: where TIKOSYN is initiated or re-initiated can provide calculations of creatinine clearance, nonitoring, and cardiac resuscitation. aff (including physicians, pharmacists, and telemetry nurses) are trained regarding the TIKOSYN it all of the program requirements. ablishment of a system, order sets, protocols, or other measures to ensure appropriate dosing aff verifies that the prescribing healthcare provider is enrolled in the TIKOSYN program prior to use. discharge, the healthcare facility must either provide a free 7-day (14-count) supply of TIKOSYN nts or ensure the patient's take-home prescription is filled.
materials. I understar	and the information will	It this Institution is correct. I confirm I have read and understand the TIKOSYN educational ill be used to enable Pfizer to identify Institutions that are eligible to dispense TIKOSYN under hare this information with others acting on its behalf and/or government agencies.
		Designated Representative Signature Date
	this form for your records. se call 1-877-TIKOSYN or MS.com.	
3 days in a facility	/ that can provide cald tion. TIKOSYN is avail	hmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of loulations of creatinine clearance, continuous electrocardiographic monitoring, and allable only to hospitals and prescribers who have received appropriate TIKOSYN dosing

TKU00130 Reference ID: 2971977 ©2011 Pfizer Inc

# T.I.P.S. PROCEDURES BOOKLET

Welcome to the T.I.P.S.™ (TIKOSYN In Pharmacy System) program

> TIKOSYN® (dofetilide) Available in Retail Pharmacy

To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.



# TIKOSYN<sup>®</sup> (dofetilide) AVAILABLE IN RETAIL PHARMACY

The T.I.P.S. procedures booklet will guide you through the program's 3 steps: Enroll, Order, and Dispense TIKOSYN. If you have any questions about TIKOSYN or any of the T.I.P.S. program procedures, or if you need additional program supplies, please call 1-877-TIKOSYN (1-877-845-6796) or visit www.TIKOSYNREMS.com.

# 1-877-TIKOSYN (1-877-845-6796)

# TIKOSYN<sup>®</sup> (dofetilide) PRESCRIBING INFORMATION

TIKOSYN<sup>®</sup> is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than I week. As described in the TIKOSYN official US prescribing package insert (enclosed), to minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation. TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.

For full prescribing information, see enclosed US prescribing package insert.



# ENROLLING IN T.I.P.S.

You must enroll in the T.I.P.S. program to order and dispense TIKOSYN° (dofetilide).

# TO ENROLL IN THE T.I.P.S. PROGRAM

- Complete the enclosed TIKOSYN Pharmacy Certification Form
- Sign and fax the form to 1-800-788-2637
- After 1 to 2 business days, confirm your enrollment by calling 1-877-TIKOSYN (1-877-845-6796) or visiting www.tikosynlist.com. You will need to enter your pharmacy DEA number
- Your signature on the enclosed TIKOSYN certification form acknowledges that the appropriate staff members in your pharmacy are aware of the procedures for dispensing TIKOSYN
- Please post the enclosed magnetic reference piece in your pharmacy as a reference for the T.I.P.S. program procedures and TIKOSYN Important Safety Information

Please see full prescribing information and patient information for TIKOSYN\* (dofetilide) capsules in T.I.P. Kit Page 56

# ORDERING TIKOSYN® (dofetilide)

Enrollment in the T.I.P.S. program must be completed before you place an order for TIKOSYN.

# TO ORDER

- Order TIKOSYN through your wholesaler
- TIKOSYN is available only in bottles of 60 capsules in
   3 dosage strengths: 125, 250, and 500 mcg
- All TIKOSYN orders will be drop-shipped directly to your pharmacy



# DISPENSING TIKOSYN® (dofetilide)

Prescriber must be a confirmed registrant in the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS) program before TIKOSYN is dispensed.

Before dispensing a prescription for TIKOSYN, you must confirm that the prescriber is a healthcare professional who has registered for the TIKOSYN REMS program and is listed in the TIKOSYN confirmed registrant database.

To verify that a prescriber is a registrant in the program, access the program database by calling the IVR (Interactive Voice Response) at 1-800-788-7353 or visiting www.tikosynlist.com and entering your pharmacy DEA number.

- At the prompt, enter the prescriber's DEA or medical license number
- The message will state, "The DEA number belongs to a prescriber who is a confirmed participant in a TIKOSYN REMS program"

Please see full prescribing information and patient information for TIKOSYN\* (dofetilide) capsules in T.I.P.S. Kit Page 58

- DO NOT dispense TIKOSYN if prescriber participation in the TIKOSYN REMS program cannot be verified. Refer these prescribers to 1-877-TIKOSYN (1-877-845-6796) to speak to a TIKOSYN Customer Representative
- After verifying the prescriber is a confirmed registrant, stamp the back of the prescription with the TIKOSYN stamp and put your initials and the date in the space provided
- Dispense TIKOSYN as prescribed in accordance with standard pharmacy practice (TIKOSYN must be ordered directly from Pfizer per individual prescription)
- Prescriptions filed according to standard pharmacy practice are subject to standard periodic review processes to ensure compliance with these conditions

We thank you for your interest in Pfizer and hope this information is helpful. If you would like additional information about TIKOSYN or the T.I.P.S. program, please call I-877-TIKOSYN (I-877-845-6796) or visit www.TIKOSYNREMS.com.



3 107% 197% AREA TKU00138C © 2011 PFIZER INC ALL RIGHTS RESERVED. PRINTED IN USA / MAY 2011



# TIKOSYN<sup>®</sup> (dofetilide) Follow the 3 steps in the T.I.P.S.™ (TIKOSYN In Pharmacy System) program

# I. ENROLL

- Your pharmacy must be enrolled in the T.I.P.S. program to order and dispense TIKOSYN
- To confirm your enrollment, call 1 877 TIKOSYN (1 877 845 6796) or visit www.tikosynlist.com

## 2. ORDER

- Order TIKOSYN through your wholesaler
- TIKOSYN orders faxed by your wholesaler are processed during normal Pfizer Customer Service business hours Monday through Friday 7:00 AM to 6:00 PM Central Standard Time

Pfizer will verify pharmacy enrollment and drop-ship TIKOSYN to the pharmacy.

# 3. DISPENSE

- On receipt of a prescription, confirm that the prescriber is a participant in the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS) program by calling the IVR (Interactive Voice Response) at I-800-788-7353 or visiting www.tikosynlist.com
- After verification, stamp the back of the prescription with the T.I.P.S. stamp and write in your initials and the date
- File the prescription
- If you cannot verify that the prescriber has registered in the TIKOSYN REMS program, call 1-877 TIKOSYN (1-877-845-6796) to speak with a TIKOSYN Customer Representative

See T.I.P.S. program procedures booklet for complete guidelines. If you have questions about TIKOSYN or T.I.P.S. program procedures, please call I-877 TIKOSYN (I-877-845-6796) or visit www.TIKOSYNREMS.com

TIKOSYN<sup>®</sup> is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than I week.

To minimize the risk of induced arrhythmia, patients initiated or re initiated on TIKOSYN should be placed for a minimum of 3 days in a facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring and cardiac resuscitation TIKOSYN is available only to hospitals and prescribers who have received appropriate TIKOSYN dosing and treatment initiation education.



6

 $\overline{\infty}$ 

<u>n</u>

# TIKOSYN<sup>®</sup>(dofetilide) IMPORTANT SAFETY INFORMATION

TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFI]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life-threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients.

TIKOSYN is indicated for the conversion of atrial fibrillation and atrial flutter to normal sinus rhythm.

TIKOSYN has not been shown to be effective in patients with paroxysmal atrial fibrillation.

TIKOSYN is contraindicated in patients with congenital or acquired long QT syndromes, a baseline QT interval or QTc >440 msec (500 msec in patients with ventricular conduction abnormalities), severe renal impairment (calculated creatinine clearance <20 mL/min), or known hypersensitivity to TIKOSYN.

TIKOSYN is also contraindicated with verapamil, hydrochlorothiazide (alone or in combination, such as with triamterene), and cation transport system inhibitors such as cimetidine, ketoconazole, trimethoprim (alone or in combination with sulfamethoxazole), prochlorperazine, and megestrol because these drugs may cause an increase in dofetilide plasma concentration.

TIKOSYN can cause serious ventricular arrhythmias, primarily torsade de pointes type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. QT interval prolongation is directly related to dofetilide plasma concentrations. Factors such as reduced creatinine clearance or certain dofetilide drug interactions will increase dofetilide plasma concentration. The risk of TdP can be reduced by controlling the plasma concentration through adjustment of the initial dofetilide dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval. Calculation of creatinine clearance and QTc for all patients must precede administration of the first dose of TIKOSYN. Renal function and QTc should be re-evaluated every 3 months or as medically warranted.

The most common adverse events reported were headache, chest pain, dizziness, respiratory tract infection, dyspnea, and nausea.

Please see full prescribing information and patient information for TIKOSYN<sup>®</sup> (dofetilide) capsules in T.I.P.S. Kit.



Pfize

2

20

6

 $\infty$ 

9

S

4

ŝ

2

\_

0

6

 $\overline{\infty}$ 

0

5

4

 $\overline{}$ 

 $\overline{}$ 

Page 62

PRINTED IN USA/MAY 2011



**U.S. Pharmaceuticals** 

#### <u>New FDA Requirement:</u> <u>Pharmacy Certification Needed to Order and Dispense TIKOSYN<sup>®</sup> (dofetilide)</u>

[Date]

Dear Dr. [insert last name]:

**Per FDA requirements, to order and dispense TIKOSYN, retail pharmacies are required to secure a one-time certification**. TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

The TIKOSYN Education Distribution Program, currently known as the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS) is required by the FDA to ensure safe use of TIKOSYN in order to mitigate the risk of induced arrhythmia by

- Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;
- Informing patients about the serious risks associated with TIKOSYN therapy.

To order and dispense TIKOSYN, you must review and follow the TIKOSYN In Pharmacy System (T.I.P.S.<sup>™</sup>) certification procedures below and enroll in the T.I.P.S. program.

- Complete the enclosed TIKOSYN Pharmacy Certification Form
- Sign and fax the form to 1-800-788-2637
- After 1 to 2 business days, confirm your certification by calling 1-877-TIKOSYN (1-877-845-6796) or visit www.tikosynlist.com. You will need to enter your pharmacy DEA number
- Your signature on the enclosed TIKOSYN certification form acknowledges that the appropriate staff members in your pharmacy are aware of the procedures for dispensing TIKOSYN
- Please post the enclosed magnetic reference piece as a reference of the T.I.P.S. program procedures and TIKOSYN contraindications in your pharmacy

Upon receipt of your certification form, a written confirmation will be sent to you. A TIKOSYN stamp will also be sent to you after certification so that you may stamp prescriptions.

Through pharmacy certification the pharmacy acknowledges that:

- The pharmacist will verify that a prescriber has participated in the TIKOSYN REMS and is confirmed in the Pfizer National TIKOSYN Database before dispensing.
- The pharmacist will stamp each prescription for distribution with the T.I.P.S. stamp, verifying that the prescriber is a confirmed participant in the TIKOSYN REMS. The pharmacist will then initial and date the TIKOSYN stamped prescription in the appropriate areas.
- The pharmacist will dispense a Medication Guide with each prescription.

Should you have any questions regarding the certification program, please call 1-877-TIKOSYN or visit www.TIKOSYNREMS.com.

Regards,

New Molton M.O.

TKU00128



**U.S. Pharmaceuticals** 

Robert Wolkow, MD, FAAFP Senior Medical Director/Team Leader U.S. Brands Established Products Business Unit



**U.S. Pharmaceuticals** 

#### New FDA Requirement:

# Pharmacy Re-certification by November 2011 Needed to Order and Dispense TIKOSYN® (dofetilide)

May 2011

Dear Dr. [insert last name]:

You previously completed the TIKOSYN In Pharmacy System (T.I.P.S.<sup>™</sup>) certification procedure and enrolled in the T.I.P.S. program, which acknowledged that you reviewed TIKOSYN materials. **Per FDA requirements, in order to continue to order and dispense TIKOSYN you are required to secure a one-time re-certification by November 2011**.

TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to recurrence of atrial fibrillation/atrial flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.

The TIKOSYN Education Distribution Program, currently known as the TIKOSYN Risk Evaluation and Mitigation Strategy (REMS) is required by the FDA to ensure safe use of TIKOSYN in order to mitigate the risk of induced arrhythmia by

- Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;
- Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;
- Informing patients about the serious risks associated with TIKOSYN therapy.

In order to continue to order and dispense TIKOSYN, you must review and follow the T.I.P.S. certification procedures below and enroll in the T.I.P.S. program.

- Complete the enclosed TIKOSYN Pharmacy Certification Form
- Sign and fax the form to 1-800-233-9141
- After 1 to 2 business days, confirm your certification by calling 1-877-TIKOSYN
  - (1-877-845-6796) or visit www.tikosynlist.com. You will need to enter your pharmacy DEA number
- Your signature on the enclosed TIKOSYN Pharmacy Certification Form acknowledges that the appropriate staff members in your pharmacy are aware of the procedures for dispensing TIKOSYN
- Please post the enclosed magnetic reference piece as a reference of the T.I.P.S. program procedures and TIKOSYN contraindications in your pharmacy

Upon receipt of your certification form, a written confirmation will be sent to you. A TIKOSYN stamp will also be sent to you after re-certification so that you may stamp prescriptions.

Through pharmacy certification the pharmacy acknowledges that:

- The pharmacist will verify that a prescriber has participated in the TIKOSYN REMS and is confirmed in the Pfizer National TIKOSYN Database before dispensing.
- The pharmacist will stamp each prescription for distribution with the T.I.P.S. stamp, verifying that the prescriber is a confirmed participant in the TIKOSYN REMS. The pharmacist will then initial and date the TIKOSYN stamped prescription in the appropriate areas.
- The pharmacist will dispense a Medication Guide with each prescription.

Should you have any questions regarding the certification program, please call (866) 249-7261 or visit www.TIKOSYNREMS.com.

Regards,

TKU00128



**U.S. Pharmaceuticals** 

Robert Wolking M.O.

Robert Wolkow, MD, FAAFP Senior Medical Director/Team Leader U.S. Brands Established Products Business Unit

# Pharmacy Certification Form

For Pfizer Internal Use Only

**Document Number** 

An authorized pharmacist must complete and sign this form as part of the TIKOSYN REMS requirements.

# PHARMACY INFORMATION\* (Please print. All information required.)

Name of Pharmacy			
Authorized Pharmacist Name			
Address 1			
Address 2			
City			
State		Zip Code	
TELEPHONE NUMBER		FAX NUMI	BER
	If you do not have a DEA		
DEA NUMBER	number, you must provide your NABP number.	NABP NUM	IBER
	-		
<ul> <li>TIKOSYN Program by submitting to Pfizer a complete to the following: <ul> <li>I will ensure that all appropriate staff are trainely will ensure that pharmacy staff will verify the prescription by accessing the system.</li> <li>I will ensure pharmacy staff stamp each press stamped prescription in the appropriate arease.</li> <li>I will ensure that the Medication Guide is provide the system of the above attestations pharmacy staff understands these special complexity.</li> </ul> </li> <li>Note that the purpose of the TIKOSYN stamp is to prior to dispensing TIKOSYN. The purpose of the pthat TIKOSYN Program procedures, to which the purpose of the pthat TIKOSYN Program procedures, to which the pthat the above information about this pharmaterials. I understand the information will be used this program. I understand Pfizer might share this information will be used the program. I understand Pfizer might share this information will be used the program.</li> </ul>	hed and have read and understar at the prescriber is certified in the scription with the provided T.I.P.S is, verifying prescriber certification wided by the pharmacy staff to the is posted or otherwise made av onditions for use of TIKOSYN. document that the pharmacist has harmacy's standard periodic rev harmacy has attested, are being macy is correct. I confirm that I h to enable Pfizer to identify Pharm	nd the T.I.P.S. program materials. e TIKOSYN program prior to disp 5. Stamp and initial and date the on status. he patient with each prescription ailable to pharmacy staff to ensu as verified the certification status iew process, in reference to the carried out.	Densing each TIKOSYN I. Ure that the s of the prescriber stamp, is to verify COSYN educational the TIKOSYN under
	Authorized	Pharmacist Signature	Date
Please retain a copy of this form for your records. For any questions please call <b>1-877-TIKOSYN</b> or visit <u>www.TIKOSYNREMS.com</u> .		Please mail or fax this docum TIKOSYN PO Box 2147 Morrisville, PA 19067-0647 <b>FAX (800) 233-9141</b>	
*For corporate pharmacy enrollment, check here . F be provided with this enrollment form. Please email the required <b>Pharmacy Information</b> detailed above for e	ne following information to TIKOSY		
To minimize the risk of induced arrhythmia, pati 3 days in a facility that can provide calculations cardiac resuscitation. TIKOSYN is available only and treatment initiation education.	of creatinine clearance, continu	uous electrocardiographic mon	itoring, and
	to TIKOSYN Risk Evaluation and atabase Manager at (800) 233-91		
TKU00133 ©2011 F	fizer Inc All rig	hts reserved	Printed in USA/April 2011

_								
	TIKOSYN• (dofetilide)							
	Risk Evaluation and Mitigation Strategy (REMS)	Please read the						
	A Risk Evaluation and Mitigation Strategy (REMS) is a strategy to manage known or potential serious risks associated with a drug product and is required by the Food and Drug Administration (FDA) to ensure that the benefits of the drug outweigh its risks.	following materials: Prescribing Information Medication Guide						
	Risks associated with TIKOSYN	TIKOSYN Treatment Guidelines						
	In order for Pfizer to communicate certain risks about TIKOSYN, Pfizer has worked with the FDA to develop materials to communicate the risk of induced arrhythmia.	To verify your certification status please click here						
	The goals of the REMS for TIKOSYN are to mitigate the risk of TIKOSYN induced arrhythmia by:							
•	<ul> <li>Ensuring that TIKOSYN is prescribed only by certified prescribers, dispensed only by certified dispensers and dispensed for use only with documentation of safe use conditions;</li> </ul>							
•	Educating health care providers about the risks and the need to initiate and re-initiate therapy in a health care facility that can provide calculations of keratinize clearance, continuous electrocardiographic monitoring, and cardiac resuscitation;							
•	Informing patients about the serious risks associated with TIKOSYN therapy.							
	Please click if you are a(n): Prescriber Pharmacy	Institution Pharmacy						
	TIKOSYN is indicated for the conversion to and maintenance of normal sinus rhythm (delay in the time to flutter) in highly symptomatic patients with atrial fibrillation/atrial flutter of greater than 1 week.	precurrence of atrial fibrillation/atrial						
	To minimize the risk of induced arrhythmia, patients initiated or re-initiated on TIKOSYN should be placed facility that can provide calculations of creatinine clearance, continuous electrocardiographic monitoring, detailed instructions regarding dose selection, see <u>DOSAGE AND ADMINISTRATION</u> ). TIKOSYN is availa prescribers who have received appropriate TIKOSYN dosing and treatment initiation education (see <u>DOS</u> full Prescribing information, please <u>click here</u> .	, and cardiac resuscitation (for able only to hospitals and						
	Copyright © 2011 Pfizer Inc. All rights reserved. TKU00141 Home   Terms of Use   Privacy Policy   Contact Us   Site	• Map						

# This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

-----

\_\_\_\_\_

/s/

\_\_\_\_\_

MARY R SOUTHWORTH 07/11/2011